Bronchiolitis Obliterans Syndrome Market

DelveInsight’s ‘Bronchiolitis Obliterans Syndrome – Market Insights, Epidemiology, and Market Forecast – 2030’ report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of Bronchiolitis Obliterans Syndrome in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.


The Bronchiolitis Obliterans Syndrome market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted Bronchiolitis Obliterans Syndrome market Size from 2018 to 2030, segmented by seven major markets. The report also covers the current Bronchiolitis Obliterans Syndrome treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying market potential.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018–2030

Bronchiolitis Obliterans Syndrome: Disease Understanding and Treatment Algorithm

Bronchiolitis Obliterans Syndrome Overview

According to the Genetic and Rare Diseases Information Center (GARD), Bronchiolitis Obliterans Syndrome (BOS) is an inflammatory condition that affects the lung’s tiniest airways, the bronchioles. The bronchioles may become damaged and inflamed in affected people, leading to extensive scarring that blocks the airways. Many different chemicals (such as nitrogen oxides, ammonia, welding fumes, or food flavoring fumes) and respiratory infections can cause lung injury, leading to bronchiolitis obliterans. It can also be associated with rheumatoid arthritis and graft-versus-host disease following a lung or hematopoietic cell transplantation.


The most common symptoms include shortness of breath, dry cough, and sometimes wheezing and fatigue in the absence of a cold or asthma. Symptoms will normally develop over a few weeks or months and flare up while exercising or manual labor. Depending on the exposure, other parts of the body may experience irritation. For example, a skin rash may develop in addition to respiratory problems. As the condition progresses, symptoms will worsen.


Bronchiolitis obliterans may result from lung injury caused by a variety of different chemicals and respiratory infections. Inhaled chemicals known to irritate the lungs and lead to the condition include chlorine, ammonia, oxides of nitrogen or sulfur dioxide, welding fumes, or food flavoring fumes (such as diacetyl). In addition, respiratory infections caused by a respiratory syncytial virus, adenovirus, or Mycoplasma pneumonia have been linked with the condition.


A diagnosis of bronchiolitis obliterans is often suspected based on the presence of characteristic signs and symptoms. Additional testing can then be ordered to support and confirm the diagnosis. These tests may include imaging studies (such as a chest CT scan), pulmonary function tests, and surgical lung biopsy.


The best treatment options and the effectiveness of the selected treatments vary based on the underlying cause and the severity of the condition. Medications often prescribed to people with bronchiolitis obliterans include certain antibiotics (called macrolide antibiotics), corticosteroids, and immunosuppressive drugs.


The combination of budesonide/formoterol, montelukast, and n-acetylcysteine significantly improved lung function and respiratory symptoms in patients with Bronchiolitis Obliterans Syndrome after allogeneic HSCT. Furthermore, combination therapy showed a better therapeutic response in patients with Bronchiolitis Obliterans Syndrome who showed prominent lung function decreases between pre-HSCT and Bronchiolitis Obliterans Syndrome diagnosis.


Bronchiolitis Obliterans Syndrome Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnosis available in the Bronchiolitis Obliterans Syndrome market to treat the condition. It also provides country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.


The DelveInsight Bronchiolitis Obliterans Syndrome market report thoroughly understands Bronchiolitis Obliterans Syndrome by including disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides the treatment algorithms and treatment guidelines for Bronchiolitis Obliterans Syndrome in the US, Europe, and Japan.

Bronchiolitis Obliterans Syndrome Epidemiology

The Bronchiolitis Obliterans Syndrome epidemiology division provides insights into the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool, trends, and assumptions.


Key Findings

The disease epidemiology covered in the report provides historical and forecasted Bronchiolitis Obliterans Syndrome epidemiology segmented as the Incident cases of Lung Transplant, Incident cases of Hematopoietic Stem Cell Transplant, Diagnosed prevalence of Bronchiolitis Obliterans Syndrome after Lung Transplant, Diagnosed prevalence of Bronchiolitis Obliterans Syndrome after Hematopoietic Stem Cell Transplants and Grade-wise Bronchiolitis Obliterans Syndrome cases. The report includes the prevalent scenario of Bronchiolitis Obliterans Syndrome in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country-wise Bronchiolitis Obliterans Syndrome Epidemiology

The epidemiology segment also provides the Bronchiolitis Obliterans Syndrome epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.


The diagnosed prevalent population of Bronchiolitis Obliterans Syndrome in the 7MM countries was estimated to be 31,570 cases in 2020.

Bronchiolitis Obliterans Syndrome Drug Chapters

The drug chapter segment of the Bronchiolitis Obliterans Syndrome report encloses the detailed analysis of Bronchiolitis Obliterans Syndrome marketed drugs and late stage (Phase-III, Phase-II/III, Phase-II, and Phase-I/II) pipeline drugs. It also helps understand the Bronchiolitis Obliterans Syndrome clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.


Currently, there is no approved or standard treatment for Bronchiolitis Obliterans Syndrome beyond azithromycin, and successful treatment is defined as stabilization or reduction in the rate of FEV1 decline. An important focus of treatment of Bronchiolitis Obliterans Syndrome patients is optimizing immunosuppression to prevent further lung allograft rejection. Augmentation of maintenance immunosuppression (typically a triple-drug regimen combining a calcineurin inhibitor, an antimetabolite, and a corticosteroid) through switching cyclosporine to tacrolimus is currently the most common initial treatment approach, although traditional immunosuppressive measures also include repeated high-dose methylprednisolone and augmentation of immunosuppressive therapy with anti-thymocyte globulin. Lung transplant recipients who have non-minimal acute cellular rejection (GradeoA2) or lymphocytic bronchiolitis on transbronchial lung biopsy specimens, augmented immunosuppression with a course of systemic steroids to prevent the development of Bronchiolitis Obliterans Syndrome (conditional recommendation, very low-quality evidence) is suggested. Long-term treatment with high-dose corticosteroids (≥30 mg/day prednisone or an equivalent) has not been shown to improve Bronchiolitis Obliterans Syndrome, while it is associated with numerous and frequent severe side effects.


The treatment of new-onset Bronchiolitis Obliterans Syndrome after HCT, a study of inhaled fluticasone, azithromycin, and montelukast (FAM) with brief steroid burst (1 mg/kg per day prednisone) and rapid taper has been reported (0.25 mg/kg per week). Other supportive care considerations include opportunities to minimize further infectious exposures and inflammatory sources while optimizing remaining pulmonary function. In several retrospective studies, extracorporeal photopheresis (ECP) treatment has been demonstrated to reduce the rate of decline in lung function associated with progressive Bronchiolitis Obliterans Syndrome, with some 25% of patients experiencing an FEV1 improvement.

Products detail in the report…


Bronchiolitis Obliterans Syndrome Emerging Drugs


Liposomal Cyclosporine A (Zambon SpA) is a novel liposomal formulation of cyclosporine A developed for inhaled delivery to the lungs. Calcineurin inhibitors (CNIs), like cyclosporine A, are highly potent immunosuppressive drugs and a cornerstone of lung transplant medicine. L CsA i is administered via a drug-specific Investigational eFlow Technology nebulizer system (PARI Pharma GmbH). The investigational drug-device combination is designed to deliver L CsA i to the site of disease in the lung. US Food and Drug Administration (FDA) had granted Fast Track designation to Liposomal Cyclosporine A for Inhalation (L CsA i), in late-stage clinical development for the treatment of Bronchiolitis Obliterans Syndrome (BOS)


Ruxolitinib (Incyte Corporation) is an oral kinase inhibitor. It inhibits JAK1 and JAK2, which mediate the signaling of several cytokines and growth factors important for hematopoiesis and immune function. JAK signaling involves recruitment of STATs (signal transducers and activators of transcription) to cytokine receptors, activation, and subsequent localization of STATs to the nucleus leading to modulation of gene expression. The drug is indicated for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis in adults; polycythemia vera in adults who have had an inadequate response to or are intolerant of hydroxyurea; and steroid-refractory acute graft-versus-host disease in adult and pediatric patients 12 years and older.

Products detail in the report…

Bronchiolitis Obliterans Syndrome Market Outlook

The Bronchiolitis Obliterans Syndrome market outlook of the report builds a detailed comprehension of the historical, current, and forecasted Bronchiolitis Obliterans Syndrome market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.


This segment gives a thorough detail of Bronchiolitis Obliterans Syndrome market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to clearly view the market at first sight.


According to DelveInsight, the Bronchiolitis Obliterans Syndrome market in the 7MM is expected to change in the study period 2018–2030.


Treatment of bronchiolitis obliterans syndrome after lung transplant/alloHSCT involves augmenting immunosuppression as it is the form of chronic rejection. Hence, increasing or adding immunosuppressive agents like tacrolimus, cyclosporine, mycophenolate mofetil, and prednisone are used to treat bronchiolitis obliterans syndrome after transplant. Azithromycin has been shown to decrease the incidence of bronchiolitis obliterans syndrome and improvement in lung function. The combination of inhaled fluticasone, oral montelukast, and azithromycin triple therapy can also decrease the decline in lung function in bronchiolitis obliterans syndrome post-HSCT. In addition to these therapies, controlling gastroesophageal reflux is also recommended to decrease bronchiolitis obliterans syndrome. In cases where bronchiolitis obliterans syndrome is progressive and severe, then retransplantation of a lung may be indicated. Extracorporeal photopheresis has also been successfully used to slow the decline in lung function from bronchiolitis obliterans syndrome. Recently, in some clinics, off-label use of nintedanib and pirfenidone has demonstrated clinical efficacy and safety. However, further studies are required to validate these drugs as a new therapeutic option for patients with Bronchiolitis Obliterans Syndrome.


Key Findings

This section includes a glimpse of the Bronchiolitis Obliterans Syndrome market in the 7MM. The market size of Bronchiolitis Obliterans Syndrome in the seven major markets was found to be USD 218.7 million in 2020.


The United States: Market Outlook

This section provides Bronchiolitis Obliterans Syndrome market size and market size by therapies of Bronchiolitis Obliterans Syndrome in the United States.


The United States accounts for the largest market size of Bronchiolitis Obliterans Syndrome compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.


In non-transplant-related bronchiolitis obliterans, removal from offending agents is essential. Immunosuppression with corticosteroids and cytotoxic agents like cyclophosphamide has been used for bronchiolitis obliterans related to rheumatoid arthritis but has not been beneficial for bronchiolitis obliterans from toxic inhalation or post-infectious etiology. In these patients, symptomatic treatment should be provided with cough suppressants, inhaled bronchodilators, and oxygen supplementation if needed.


Bronchiolitis Obliterans Syndrome after lung transplantation remains a very challenging condition, confronting the patient and the clinician with many problems and an insecure future. However, pharmaceutical companies are constantly working to bring innovative treatment soon in the market which could meet the unmet demands for Bronchiolitis Obliterans Syndrome patients. Currently, Zambon’s phase III asset, Liposomal cyclosporine A, is the only key asset in clinical development. Other assets include Ruxolitinib, Alvelestat, and Itacitinib.


EU-5 Countries: Market Outlook

The total Bronchiolitis Obliterans Syndrome market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are also mentioned.


Japan Market Outlook

The total Bronchiolitis Obliterans Syndrome market size and market size by therapies of Bronchiolitis Obliterans Syndrome in Japan are also mentioned.

Bronchiolitis Obliterans Syndrome Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2018–2030. The analysis covers Bronchiolitis Obliterans Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug. 


This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Bronchiolitis Obliterans Syndrome Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II/III, Phase II, and Phase I/II stage. It also analyses Bronchiolitis Obliterans Syndrome key players involved in developing targeted therapeutics.


Major players include Lifemax Laboratories and AnaptysBio, whose key products are expected to get launched in the US market by 2030.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Bronchiolitis Obliterans Syndrome emerging therapies.

KOL Views

To keep up with current market trends, we take KOLs and SME’s opinion working in the Bronchiolitis Obliterans Syndrome domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or Bronchiolitis Obliterans Syndrome market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform a Competitive and Market Intelligence analysis of the Bronchiolitis Obliterans Syndrome market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Bronchiolitis Obliterans Syndrome, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
  • Comprehensive insight has been provided into the Bronchiolitis Obliterans Syndrome epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Bronchiolitis Obliterans Syndrome is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the Bronchiolitis Obliterans Syndrome market, historical and forecasted, is included in the report, covering drug outreach in the 7MM.
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global Bronchiolitis Obliterans Syndrome market.

Report Highlights

  • In the coming years, the Bronchiolitis Obliterans Syndrome market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Bronchiolitis Obliterans Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Bronchiolitis Obliterans Syndrome. The launch of emerging therapies will significantly impact the Bronchiolitis Obliterans Syndrome market
  • A better understanding of disease pathogenesis will also contribute to developing novel therapeutics for Bronchiolitis Obliterans Syndrome.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competitor, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Bronchiolitis Obliterans Syndrome Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Bronchiolitis Obliterans Syndrome Pipeline Analysis
  • Bronchiolitis Obliterans Syndrome Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Bronchiolitis Obliterans Syndrome Report Key Strengths

  • 10-years Forecast
  • 7MM Coverage
  • Bronchiolitis Obliterans Syndrome Epidemiology Segmentation
  • Key Competitors
  • Highly Analyzed Market
  • Drugs Uptake

Bronchiolitis Obliterans Syndrome Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Bronchiolitis Obliterans Syndrome Market share (%) distribution in 2018, and how would it look like in 2030?
  • What would be the Bronchiolitis Obliterans Syndrome total market Size and market Size by therapies across the 7MM during the forecast period (2018–2030)?
  • What are the key findings pertaining to the market across 7MM, and which country will have the largest Bronchiolitis Obliterans Syndrome market Size during the forecast period (2018–2030)?
  • At what CAGR, the Bronchiolitis Obliterans Syndrome market is expected to grow in the 7MM during the forecast period (2018–2030)?
  • What would be the Bronchiolitis Obliterans Syndrome market outlook across the 7MM during the forecast period (2018–2030)?
  • What would be the Bronchiolitis Obliterans Syndrome market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?


Epidemiology Insights:

  • What are the disease risk, burden, and unmet needs of Bronchiolitis Obliterans Syndrome?
  • What is the historical Bronchiolitis Obliterans Syndrome patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Bronchiolitis Obliterans Syndrome in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Bronchiolitis Obliterans Syndrome?
  • Out of all 7MM countries, which country would have the highest prevalence of Bronchiolitis Obliterans Syndrome during the forecast period (2018–2030)?
  • At what CAGR the population is expected to grow in the 7MM during the forecast period (2018–2030)?


Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Bronchiolitis Obliterans Syndrome?
  • What are the current treatment guidelines for treating Bronchiolitis Obliterans Syndrome in the USA, Europe, and Japan?
  • What are the Bronchiolitis Obliterans Syndrome marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Bronchiolitis Obliterans Syndrome?
  • How many therapies are developed by each company for the treatment of Bronchiolitis Obliterans Syndrome?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of Bronchiolitis Obliterans Syndrome?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Bronchiolitis Obliterans Syndrome therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Bronchiolitis Obliterans Syndrome and their status?
  • What are the key designations that have been granted for the emerging therapies for Bronchiolitis Obliterans Syndrome?
  • What are the global historical and forecasted market for Bronchiolitis Obliterans Syndrome?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Bronchiolitis Obliterans Syndrome market
  • To understand the future market competition in the Bronchiolitis Obliterans Syndrome market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Bronchiolitis Obliterans Syndrome in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the Bronchiolitis Obliterans Syndrome market.
  • To understand the future market competition in the Bronchiolitis Obliterans Syndrome market.

1. Key Insight:

2. Report Introduction

3. Bronchiolitis Obliterans Syndrome (BOS) Market Overview at a Glance

3.1. Market Share (%) Distribution of BOS in 2018

3.2. Market Share (%) Distribution of BOS in 2030

4. Executive Summary of Bronchiolitis Obliterans Syndrome (BOS)

5. Disease Background and Overview

5.1. Introduction

5.2. Clinical Manifestations

5.3. Risk factors 24

5.4. Classification

5.5. Pathogenesis

5.6. Diagnosis

5.6.1. Differential Diagnosis

5.7. Treatment

5.7.1. Treatment Guidelines for the management of BOS

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. 7MM Total Diagnosed Prevalence of BOS

6.3. Epidemiology of Bronchiolitis Obliterans Syndrome (BOS)

6.4. The United States

6.4.1. Incident cases of Lung Transplant in the US

6.4.2. Incident cases of Hematopoietic Stem Cell Transplant in the US

6.4.3. Diagnosed prevalence of BOS after Lung Transplant in the US

6.4.4. Diagnosed prevalence of BOS after Hematopoietic Stem Cell Transplants in the US

6.4.5. Grade-wise BOS cases in the US

6.5. EU5

6.5.1. Germany

6.5.1.1. Incident cases of Lung Transplant in Germany

6.5.1.2. Incident cases of Hematopoietic Stem Cell Transplant in Germany

6.5.1.3. Diagnosed prevalence of BOS after Lung Transplant in Germany

6.5.1.4. Diagnosed prevalence of BOS after Hematopoietic Stem Cell Transplants in Germany

6.5.1.5. Grade-wise BOS cases in Germany

6.5.2. France

6.5.2.1. Incident cases of Lung Transplant in France

6.5.2.2. Incident cases of Hematopoietic Stem Cell Transplant in France

6.5.2.3. Diagnosed prevalence of BOS after Lung Transplant in France

6.5.2.4. Diagnosed prevalence of BOS after Hematopoietic Stem Cell Transplants in France

6.5.2.5. Grade-wise BOS cases in France

6.5.3. Italy

6.5.3.1. Incident cases of Lung Transplant in Italy

6.5.3.2. Incident cases of Hematopoietic Stem Cell Transplant in Italy 64

6.5.3.3. Diagnosed prevalence of BOS after Lung Transplant in Italy

6.5.3.4. Diagnosed prevalence of BOS after Hematopoietic Stem Cell  Transplants in Italy

6.5.3.5. Grade-wise BOS cases in Italy

6.5.4. Spain

6.5.4.1. Incident cases of Lung Transplant in Spain

6.5.4.2. Incident cases of Hematopoietic Stem Cell Transplant in Spain

6.5.4.3. Diagnosed prevalence of BOS after Lung Transplant in Spain

6.5.4.4. Diagnosed prevalence of BOS after Hematopoietic Stem Cell Transplants in Spain

6.5.4.5. Grade-wise BOS cases in Spain

6.5.5. The United Kingdom

6.5.5.1. Incident cases of Lung Transplant in the United Kingdom

6.5.5.2. Incident cases of Hematopoietic Stem Cell Transplant in the United Kingdom

6.5.5.3. Diagnosed prevalence of BOS after Lung Transplant in the United Kingdom

6.5.5.4. Diagnosed prevalence of BOS after Hematopoietic Stem Cell Transplants in the United Kingdom

6.5.5.5. Grade-wise BOS cases in the United Kingdom

6.6. Japan

6.6.1. Incident cases of Lung Transplant in Japan

6.6.2. Incident cases of Hematopoietic Stem Cell Transplant in Japan

6.6.3. Diagnosed prevalence of BOS after Lung Transplant in Japan

6.6.4. Diagnosed prevalence of BOS after Hematopoietic Stem Cell Transplants in Japan

6.6.5. Grade-wise BOS cases in Japan

7. Organizations contributing toward Bronchiolitis Obliterans Syndrome (BOS)

8. Case Reports

9. Patient Journey

10. Emerging Therapies

10.1. Key Cross Competition

10.2. Liposomal Cyclosporine A: Zambon SpA

10.2.1. Drug Description

10.2.2. Other development activities

10.2.3. Clinical Developments

10.2.3.1. Clinical trials information

10.2.4. Product profile

11. Other Assets

11.1. Key Cross Other Assets

11.2. Itacitinib: Incyte Corporation

11.2.1. Drug Description

11.2.2. Other development activities

11.2.3. Clinical Developments

11.2.3.1. Clinical trials information

11.2.3.2. Product profile

11.3. Ruxolitinib: Incyte Corporation

11.3.1. Drug Description

11.3.2. Other development activity

11.3.3. Clinical Development

11.3.3.1. Clinical trials information

11.3.3.2. Product profile

11.4. Alvelestat: Mereo BioPharma

11.4.1. Drug Description

11.4.2. Other development activity

11.4.3. Clinical Development

11.4.3.1. Clinical trials information

11.4.4. Safety and Efficacy

11.4.5. Product profile

12. Bronchiolitis Obliterans Syndrome: Seven Major Market Analysis

12.1. Key Findings

12.2. Market Size of BOS in 7MM

12.3. Market Outlook

12.4. United States Market Size

12.4.1. Total Market Size of BOS in the United States

12.4.2. Market Size of BOS by therapies in the United States

12.5. EU-5 Market Size

12.5.1. Germany

12.5.1.1. Total Market size of BOS in Germany

12.5.1.2. Market Size of BOS by therapies in Germany

12.5.2. France

12.5.2.1. Total Market size of BOS in France

12.5.2.2. Market Size of BOS by Therapies in France

12.5.3. Italy

12.5.3.1. Total Market size of BOS in Italy

12.5.3.2. Market Size of BOS by Therapies in Italy

12.5.4. Spain

12.5.4.1. Total Market size of BOS in Spain

12.5.4.2. Market Size of BOS by Therapies in Spain

12.5.5. United Kingdom

12.5.5.1. Total Market size of BOS in the United Kingdom

12.5.5.2. Market Size of BOS by Therapies in the United Kingdom

12.6. Japan

12.6.1. Total Market size of BOS in Japan

12.6.2. Market Size of BOS by therapies in Japan

13. Market Drivers

14. Market Barriers

15. SWOT Analysis

16. Unmet Needs

17. KOL Views

18. Appendix

18.1. Bibliography

18.2. Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

List of Table

Table 1: Summary of Bronchiolitis Obliterans Syndrome, Epidemiology, and Key Events (2018–2030)

Table 2: Diagnosed Prevalence of BOS in 7MM (2018–2030)

Table 3: Incident cases of Lung Transplant in the United States (2018–2030)

Table 4: Incident cases of Hematopoietic Stem Cell Transplant in the United States (2018–2030)

Table 5: Diagnosed prevalence of BOS after Lung Transplant in the United States (2018–2030)

Table 6: Diagnosed prevalence of BOS after Hematopoietic Stem Cell Transplants in the United States (2018–2030)

Table 7: Grade-wise BOS cases in the United States (2018–2030)

Table 8: Incident cases of Lung Transplant in Germany (2018–2030)

Table 9: Incident cases of Hematopoietic Stem Cell Transplant in Germany (2018–2030)

Table 10: Diagnosed prevalence of BOS after Lung Transplant in Germany (2018–2030)

Table 11: Diagnosed prevalence of BOS after Hematopoietic Stem Cell Transplants in Germany (2018–2030)

Table 12: Grade-wise BOS cases in Germany (2018–2030)

Table 13: Incident cases of Lung Transplant in France (2018–2030)

Table 14: Incident cases of Hematopoietic Stem Cell Transplant in France (2018–2030)

Table 15: Diagnosed prevalence of BOS after Lung Transplant in France (2018–2030)

Table 16: Diagnosed prevalence of BOS after Hematopoietic Stem Cell Transplants in France (2018–2030)

Table 17: Grade-wise BOS cases in France (2018–2030)

Table 18: Incident cases of Lung Transplant in Italy (2018–2030)

Table 19: Incident cases of Hematopoietic Stem Cell Transplant in Italy (2018–2030)

Table 20: Diagnosed prevalence of BOS after Lung Transplant in Italy (2018–2030)

Table 21: Diagnosed prevalence of BOS after Hematopoietic Stem Cell Transplants in Italy (2018–2030)

Table 22: Grade-wise BOS cases in Italy (2018–2030)

Table 23: Incident cases of Lung Transplant in Spain (2018–2030)

Table 24: Incident cases of Hematopoietic Stem Cell Transplant in Spain (2018–2030)

Table 25: Diagnosed prevalence of BOS after Lung Transplant in Spain (2018–2030)

Table 26: Diagnosed prevalence of BOS after Hematopoietic Stem Cell Transplants in Spain (2018–2030)

Table 27: Grade-wise BOS cases in Spain (2018–2030)

Table 28: Incident cases of Lung Transplant in the United Kingdom (2018–2030)

Table 29: Incident cases of Hematopoietic Stem Cell Transplant in the United Kingdom (2018–2030)

Table 30: Diagnosed prevalence of BOS after Lung Transplant in the United Kingdom (2018–2030)

Table 31: Diagnosed prevalence of BOS after Hematopoietic Stem Cell Transplants in the United Kingdom (2018–2030)

Table 32: Grade-wise BOS cases in the United Kingdom (2018–2030)

Table 33: Incident cases of Lung Transplant in Japan (2018–2030)

Table 34: Incident cases of Hematopoietic Stem Cell Transplant in Japan (2018–2030)

Table 35: Diagnosed prevalence of BOS after Lung Transplant in Japan (2018–2030)

Table 36: Diagnosed prevalence of BOS after Hematopoietic Stem Cell Transplants in Japan (2018–2030)

Table 37: Grade-wise BOS cases in Japan (2018–2030)

Table 38: Organizations contributing toward Bronchiolitis Obliterans Syndrome (BOS)

Table 39: Seven Major Market Size of BOS in USD Million (2018–2030)

Table 40: The United States Market Size of BOS in USD Million (2018–2030)

Table 41: The United States Market Size of BOS by Therapies in USD Million (2018–2030)

Table 42: Germany Market Size of BOS in USD Million (2018–2030)

Table 43: Germany Market Size of BOS by Therapies in USD Million (2018–2030)

Table 44: France Market Size of BOS in USD Million (2018–2030)

Table 45: France Market Size of BOS by Therapies in USD Million (2018–2030)

Table 46: Italy Market Size of BOS in USD Million (2018–2030)

Table 47: Italy Market Size of BOS by Therapies in USD Million (2018–2030)

Table 48: Spain Market Size of BOS in USD Million (2018–2030)

Table 49: Spain Market Size of BOS by Therapies in USD Million (2018–2030)

Table 50: The United Kingdom Market Size of BOS in USD Million (2018–2030)

Table 51: The United Kingdom Market Size of BOS by Therapies in USD Million (2018–2030)

Table 52: Japan Market Size of BOS in USD Million (2018–2030)

Table 53: Japan Market Size of BOS by Therapies in USD Million (2018–2030)

List of Figures

Figure 1: Clinical manifestations of BOS

Figure 2: Risk Factors Involved in BOS

Figure 3: Pathogenesis of BOS

Figure 4: Diagnostic Methods for BOS

Figure 5: Algorithm for the Diagnosis of BOS

Figure 6: Differential Diagnosis of Delayed Post-transplant Lung Function Decline

Figure 7: Algorithm for the Management of BOS

Figure 8: International Society for Heart and Lung Transplantation (ISHLT)/American Thoracic Society (ATS)/European Respiratory Society (ERS) Guidelines for the Management of BOS

Figure 9: Total Diagnosed Prevalent Population of BOS in 7MM (2018–2030)

Figure 10: Incident cases of Lung Transplant in the United States (2018–2030)

Figure 11: Incident cases of Hematopoietic Stem Cell Transplant in the United States (2018–2030)

Figure 12: Diagnosed prevalence of BOS after Lung Transplant in the United States (2018–2030)

Figure 13: Diagnosed prevalence of BOS after Hematopoietic Stem Cell Transplants in the United States (2018–2030)

Figure 14: Grade-wise BOS cases in the United States (2018–2030)

Figure 15: Incident cases of Lung Transplant in Germany (2018–2030)

Figure 16: Incident cases of Hematopoietic Stem Cell Transplant in Germany (2018–2030)

Figure 17: Diagnosed prevalence of BOS after Lung Transplant in Germany (2018–2030)

Figure 18: Diagnosed prevalence of BOS after Hematopoietic Stem Cell Transplants in Germany (2018–2030)

Figure 19: Grade-wise BOS cases in Germany (2018–2030)

Figure 20: Incident cases of Lung Transplant in France (2018–2030)

Figure 21: Incident cases of Hematopoietic Stem Cell Transplant in France (2018–2030)

Figure 22: Diagnosed prevalence of BOS after Lung Transplant in France (2018–2030)

Figure 23: Diagnosed prevalence of BOS after Hematopoietic Stem Cell Transplants in France (2018–2030)

Figure 24: Grade-wise BOS cases in France (2018–2030)

Figure 25: Incident cases of Lung Transplant in Italy (2018–2030)

Figure 26: Incident cases of Hematopoietic Stem Cell Transplant in Italy (2018–2030)

Figure 27: Diagnosed prevalence of BOS after Lung Transplant in Italy (2018–2030)

Figure 28: Diagnosed prevalence of BOS after Hematopoietic Stem Cell Transplants in Italy (2018–2030)

Figure 29: Grade-wise BOS cases in Italy (2018–2030)

Figure 30: Incident cases of Lung Transplant in Spain (2018–2030)

Figure 31: Incident cases of Hematopoietic Stem Cell Transplant in Spain (2018–2030)

Figure 32: Diagnosed prevalence of BOS after Lung Transplant in Spain (2018–2030)

Figure 33: Diagnosed prevalence of BOS after Hematopoietic Stem Cell Transplants in Spain (2018–2030)

Figure 34: Grade-wise BOS cases in Spain (2018–2030)

Figure 35: Incident cases of Lung Transplant in the United Kingdom (2018–2030)

Figure 36: Incident cases of Hematopoietic Stem Cell Transplant in the United Kingdom (2018–2030)

Figure 37: Diagnosed prevalence of BOS after Lung Transplant in the United Kingdom (2018–2030)

Figure 38: Diagnosed prevalence of BOS after Hematopoietic Stem Cell Transplants in the United Kingdom (2018–2030)

Figure 39: Grade-wise BOS cases in the United Kingdom (2018–2030)

Figure 40: Incident cases of Lung Transplant in Japan (2018–2030)

Figure 41: Incident cases of Hematopoietic Stem Cell Transplant in Japan (2018–2030)

Figure 42: Diagnosed prevalence of BOS after Lung Transplant in Japan (2018–2030)

Figure 43: Diagnosed prevalence of BOS after Hematopoietic Stem Cell Transplants in Japan (2018–2030)

Figure 44: Grade-wise BOS cases in Japan (2018–2030)

Figure 45: 7 Major Market Size of BOS in USD Million (2018–2030)

Figure 46: Market Size of BOS in the United States, USD Million (2018–2030)

Figure 47: The United States Market Size of BOS by Therapies in USD Million (2018–2030)

Figure 48: Market Size of BOS in Germany, USD Million (2018–2030)

Figure 49: Germany Market Size of BOS by Therapies in USD Million (2018–2030)

Figure 50: Market Size of BOS in France, USD Million (2018–2030)

Figure 51: France Market Size of BOS by Therapies in USD Million (2018–2030)

Figure 52: Market Size of BOS in Italy, USD Million (2018–2030)

Figure 53: Italy Market Size of BOS by Therapies in USD Million (2018–2030)

Figure 54: Market Size of BOS in Spain, USD Million (2018–2030)

Figure 55: Spain Market Size of BOS by Therapies in USD Million (2018–2030)

Figure 56: Market Size of BOS in the United Kingdom, USD Million (2018–2030)

Figure 57: The United Kingdom Market Size of BOS by Therapies in USD Million (2018–2030)

Figure 58: Market Size of BOS in Japan, USD Million (2018–2030)

Figure 59: Japan Market Size of BOS by Therapies in USD Million (2018–2030)

• Zambon SpA

• Incyte Corporation

• Mereo BioPharma

  • Tags:
  • Bronchiolitis Obliterans Syndrome m...
  • Bronchiolitis Obliterans Syndrome...
  • Bronchiolitis Obliterans Syndrome...
  • Bronchiolitis Obliterans Syndrome...
  • Bronchiolitis Obliterans Syndrome...
  • Bronchiolitis Obliterans Syndrome...
  • Bronchiolitis Obliterans Syndrome...
  • Bronchiolitis Obliterans Syndrome...
  • Bronchiolitis Obliterans Syndrome...
  • Bronchiolitis Obliterans Syndrome...
  • Bronchiolitis Obliterans Syndrome...
  • Bronchiolitis Obliterans Syndrome...
  • Bronchiolitis Obliterans Syndrome...
  • Bronchiolitis Obliterans Syndrome

Forward to Friend

Need A Quote